Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
13 Dec 2023
bởiAudrey Abella
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
13 Dec 2023








